Correspondence 0001193125-23-151169 from BIOCEPT INC (BIOCQ) (CIK 0001044378)
BIOCEPT INC (BIOCQ) (CIK 0001044378)
Date: May 23, 2023 · CIK: 0001044378 · Accession: 0001193125-23-151169
AI Filing Summary & Sentiment
File numbers found in text: 333-271355
Letter
Biocept, Inc.
5810 Nancy Ridge Drive
San Diego, CA 92121
May 23, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jessica Ansart
Re: Biocept, Inc.
Registration Statement on Form S-1, as amended (File No. 333-271355)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Biocept, Inc. (the “Company”) hereby withdraws its request, dated May 19, 2023, that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Time, on May 22, 2023. Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement and declare the Registration Statement effective as of 4:15 p.m., Eastern Time, on May 24, 2023, or as soon thereafter as possible, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request. The Company hereby authorizes each of Charles J. Bair and Asa M. Henin of Cooley LLP, counsel to the Company, to make such a request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Asa M. Henin of Cooley LLP at (858) 550-6104, or in his absence, Charles J. Bair of Cooley LLP at (858) 550-6142.
Very truly yours,
Biocept, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 23, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Request for Acceleration of Effective Date Ladies and Gentlemen: Biocept, Inc. (the “Company”) hereby withdraws its request, dated May 19, 2023, that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Time, on May 22, 2023. Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement and declare the Registration Statement effective as of 4:15 p.m., Eastern Time, on May 24, 2023, or as soon thereafter as possible, or at such other time as the Company or its counsel may request by telephone to the staff of the Commission. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP confirming this request. The Company hereby authorizes each of Charles J. Bair and Asa M. Henin of Cooley LLP, counsel to the Company, to make such a request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Asa M. Henin of Cooley LLP at (858) 550-6104, or in his absence, Charles J. Bair of Cooley LLP at (858) 550-6142. Very truly yours, Biocept, Inc. /s/ Samuel D. Riccitelli By: Samuel D. Riccitelli Title: Interim President and Chief Executive Officer